Nuveen Asset Management LLC Grows Position in Danaher Co. (NYSE:DHR)

Nuveen Asset Management LLC lifted its position in shares of Danaher Co. (NYSE:DHR - Free Report) by 2.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,068,948 shares of the conglomerate's stock after purchasing an additional 111,894 shares during the period. Nuveen Asset Management LLC owned 0.56% of Danaher worth $934,027,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Numerai GP LLC acquired a new position in Danaher during the 4th quarter worth approximately $1,983,000. OMERS ADMINISTRATION Corp increased its stake in Danaher by 74.3% in the 4th quarter. OMERS ADMINISTRATION Corp now owns 50,202 shares of the conglomerate's stock worth $11,524,000 after purchasing an additional 21,397 shares during the period. Obermeyer Wealth Partners boosted its position in shares of Danaher by 25.6% during the fourth quarter. Obermeyer Wealth Partners now owns 2,012 shares of the conglomerate's stock valued at $462,000 after purchasing an additional 410 shares in the last quarter. Minot DeBlois Advisors LLC purchased a new position in shares of Danaher in the fourth quarter worth $1,606,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Danaher by 7.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 63,534 shares of the conglomerate's stock worth $14,584,000 after acquiring an additional 4,388 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Analyst Ratings Changes

DHR has been the topic of a number of research analyst reports. Jefferies Financial Group dropped their price target on Danaher from $260.00 to $230.00 and set a "buy" rating on the stock in a research note on Tuesday, April 22nd. Barclays increased their target price on Danaher from $205.00 to $215.00 and gave the company an "overweight" rating in a research note on Tuesday, April 22nd. UBS Group cut their target price on Danaher from $275.00 to $240.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. Guggenheim reissued a "buy" rating and set a $250.00 price objective on shares of Danaher in a research report on Wednesday, April 23rd. Finally, JPMorgan Chase & Co. cut their target price on Danaher from $280.00 to $260.00 and set an "overweight" rating for the company in a research report on Tuesday, April 22nd. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $264.40.

Insider Activity

In other news, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the sale, the executive vice president now directly owns 15,179 shares in the company, valued at approximately $3,005,442. This trade represents a 51.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the transaction, the chairman now owns 3,105,808 shares of the company's stock, valued at $611,036,665.92. This represents a 28.70% decrease in their position. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by insiders.

Danaher Price Performance

Danaher stock traded down $0.89 during midday trading on Monday, reaching $195.22. The company's stock had a trading volume of 814,429 shares, compared to its average volume of 3,443,901. The firm has a market capitalization of $139.71 billion, a PE ratio of 36.96, a P/E/G ratio of 2.66 and a beta of 0.80. The stock's 50 day simple moving average is $196.87 and its 200 day simple moving average is $217.27. Danaher Co. has a fifty-two week low of $171.00 and a fifty-two week high of $281.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.26. Danaher had a return on equity of 10.82% and a net margin of 16.33%. The company had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. On average, equities research analysts forecast that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.66%. Danaher's dividend payout ratio (DPR) is presently 24.85%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.